This life-extending hormone therapy is at last available on the NHS. It will benefit around 4,000 men each year, diagnosed with advanced prostate cancer and where standard chemotherapy is unsuitable. This is seen as a great achievement although NICE (thr National Institute for Clinical Excellence) have yet to approve other treatments such as abiraterone or apalutamide. And of course there is still no national screening for prostate cancer.